Global Sedation in ICU Setting Market Report and Forecast 2024-2032

Global Sedation in ICU Setting Market Outlook

The global sedation in ICU setting market size reached a value of around USD 3.16 billion in 2023. The market is expected to grow at a CAGR of 5.60% during the forecast period of 2024-2032 to attain a value of USD 5.15 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Trends in the Market

A state of serenity, relaxation, or sleepiness brought on by medicines is referred to as sedation. During medical or surgical procedures, sedation may be used to help people cope with severely stressful situations or to reduce anxiety. In the ICU setting, sedative drugs are frequently used primarily to alleviate agitation and anxiety, which can be brought on by a variety of different diseases.

• The global market for sedation in ICU settings is rapidly growing due to the increasing geriatric population and their susceptibility to numerous chronic conditions.

• The number of patients being admitted to ICUs and critical care units is rising due to the rising cases of comorbid diseases in the elderly population. This is stimulating the market growth.

• The global sedation in ICU setting market is experiencing growth prospects due to investments in healthcare facility improvement and the adoption of innovations like proper ventilation, larger space for more visiting family members, better drainage systems, and others. Additionally, the increase in peoples' disposable income has pushed them to choose better healthcare options and facilities for their loved ones. This will aid the market expansion in the coming years.

• Sedation is frequently used in the intensive care unit to reduce anxiety and increase comfort in patients who need mechanical ventilation. Critically ill patients typically receive analgesia and sedation to reduce their pain and anxiety, facilitate invasive procedures, reduce their stress levels and oxygen consumption, and improve synchronisation with mechanical breathing. Thus, these advantages contribute to the global market's expansion.

Global Sedation in ICU Setting Market Analysis

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on drug class, the market is segmented into propofol, benzodiazepines, dexmedetomidine, and remifentanil, among others. The regional markets for sedation in ICU setting can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global sedation in ICU setting market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.  

• Medtronic plc

• AstraZeneca plc

• GlaxoSmithKline plc

• Mylan N.V.

• Teva Pharmaceutical Industries Ltd.

• B. Braun Medical

• Others

Market Share by Drug Class

Based on drug class, the market was dominated by propofol in the historical period. During the forecast period, the segment is expected to dominate the sedation in ICU setting market. This occurs as a result of propofol's rapid uptake as a painkiller and agitation suppressant in mechanical breathing. In the upcoming years, this will help propofol's market expansion, along with the introduction of generic products. 

In order to sedate patients in the ICU, propofol is frequently given as a continuous intravenous infusion. Propofol has special qualities that allow it to penetrate the blood-brain barrier quickly, which causes sedation to start working quickly. Additionally, coronavirus (COVID-19) patients in the intensive care unit (ICU) who require mechanical breathing may be sedated with propofol.

Market Share by Region

It is anticipated that North America will dominate the global sedation in ICU setting market. This is because of the increasing older population with comorbid illnesses and increasing number of beds for critical care in developed countries like Canada and the United States. The region's expansion is also being fuelled by the rise in infectious disorders including sepsis and respiratory conditions that require ICU hospitalisation.

Growing hospital ICUs, expanding healthcare infrastructure, and an increase in ICU admissions are some of the key drivers of the global sedation in ICU setting market in developing nations in the Asia Pacific and Latin American regions.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

Medtronic plc, founded in 1949 is a leading manufacturer of medical equipment and treatments, including pacemakers, insulin pumps, and treatments for diabetes. It is best recognised for its ground-breaking cardiac devices, including pacemakers that are battery-operated and small. However, it has also put cutting-edge technologies into the market.

AstraZeneca plc, a holding company with its headquarters in the United Kingdom is involved in the creation, production, and research of pharmaceutical goods. To treat diseases in the cancer, cardiovascular, infection, neurological, respiratory, gastrointestinal, and inflammatory domains, the business develops, produces, and sells pharmaceutical and biotechnology products.

GlaxoSmithKline plc, one of the biggest research-based pharmaceutical firms in the world is headquartered in England and produces, promotes, and distributes products for human health. For the purpose of preventing and treating disease, it creates novel vaccinations and specialised medications. 

Other market players include Mylan N.V., Teva Pharmaceutical Industries Ltd., and B. Braun Medical, among others.

Key Highlights of the Report